Idelalisib (Zydelig; CAL-101; CAS 870281-82-6): NIOSH HD Category 1 FORTIETH Mechanism Class [PI3Kδ-Selective Lipid Kinase Inhibitor — FIRST PI3K INHIBITOR EVER FDA APPROVED (NDA 205858; July 23, 2014; Calistoga Pharmaceuticals CAL-101 → Gilead ∼$375M; Fatal Hepatotoxicity/Colitis/Pneumonitis BBW; Treg Immune Mechanism; 2016 FDA Clinical Hold; C22H18FN7O; MW ∼415.4 g/mol)] + CLL Study 312-0116 PFS HR 0.15 (ORR 81% vs 13%) + DELTA FL ORR 57% (mDOR 11.4 mo) + PI3Kδ Leukocyte-Restricted BCR/TCR Signaling; Gilead Foster City CA 52M 18yr Cority ÷10; Thermo Fisher Greenville NC 46F 14yr VelocityEHS ÷10; Fred Hutchinson Seattle WA 45M 12yr EHS Insight ÷10; Glyphward Threshold 22; 592nd Adversarial Attack; 134th Long-Form Blog

Idelalisib (Zydelig®; CAL-101; CAS 870281-82-6; C22H18FN7O; MW ∼415.4 g/mol; purinone + quinazolinone + 4-fluorobenzylpiperidine scaffold; NIOSH HD Category 1; Gilead Sciences NDA 205858 July 23, 2014; MECHANISM: FORTIETH MECHANISM CLASS in the 592-ATTACK GLYPHWARD ADVERSARIAL PORTFOLIO — PI3Kδ-SELECTIVE PHOSPHOINOSITIDE 3-KINASE (LIPID KINASE) INHIBITOR; THE FIRST PI3K INHIBITOR EVER FDA APPROVED IN ANY INDICATION; HISTORICAL CONTEXT: Calistoga Pharmaceuticals CAL-101 discovery 2004–2011; Gilead Sciences acquisition August 2011 ∼$375M upfront (∼$600M total with milestones); idelalisib became Gilead’s first oncology small-molecule kinase NDA; PI3K SUBSTRATE CLASS: phosphoinositide 3-kinase lipid kinase; phosphorylates PIP2 (phosphatidylinositol-4,5-bisphosphate) 3′-OH → PIP3 (phosphatidylinositol-3,4,5-trisphosphate); PH-domain protein recruitment [AKT; BTK; PDK1] → AKT/mTOR survival signaling; B-CELL RECEPTOR CONSTITUTIVE ACTIVATION IN CLL/FL → PI3Kδ the dominant PI3K isoform in lymphocyte BCR signaling; PI3Kδ SELECTIVITY: PI3Kδ IC50 ∼19 nM; PI3Kα >820 nM [>43-fold]; PI3Kβ >565 nM [>29-fold]; PI3Kγ ∼89 nM [∼5-fold]; leukocyte-restricted PI3Kδ expression in B cells/T cells/NK cells (vs ubiquitous PI3Kα/PI3Kβ); FATAL TOXICITY BBW: Fatal and Serious Toxicities Boxed Warning (hepatotoxicity Grade ≥3 ∼35–50%; diarrhea/colitis Grade ≥3 ∼19%; pneumonitis ∼4%; intestinal perforation); ALL IMMUNE-MEDIATED VIA TREG DEPLETION: FoxP3+ Treg cells require PI3Kδ for survival; PI3Kδ inhibition → Treg depletion → loss of peripheral tolerance → autoreactive T-cell hepatitis/colitis/pneumonitis; MECHANISTICALLY DISTINCT from direct-toxicity kinase inhibitors; 2016 FDA CLINICAL HOLD: January 2016 on first-line idelalisib combination trials; excess immune-mediated deaths (PCP; CMV reactivation; fatal immune-mediated hepatotoxicity) in treatment-naïve patients; STUDY 312-0116 [Phase 3; relapsed CLL; idelalisib+rituximab vs placebo+rituximab; n=220]: PFS HR 0.15 [p<0.0001; early stopping; ORR 81% vs 13%; del(17p) ORR 82%]; DELTA [Phase 2; relapsed FL ≥2 prior lines; n=72]: ORR 57% [mDOR 11.4 mo]; NDA 205858 FIRST PI3K INHIBITOR EVER: July 23, 2014; 5 years before alpelisib [NDA 212526; May 2019; PI3Kα]; 3 years before copanlisib [NDA 209936; September 2017; pan-PI3K IV]; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL; NIOSH HD Category 1; GHS H340 H350 H361; 592nd adversarial attack; 134th long-form blog).

FORTIETH MECHANISM CLASS: PI3K Lipid Kinase Inhibition and Idelalisib as the Chronological Founder of PI3K-Targeted FDA-Approved Medicine

The first thirty-nine mechanism classes in the Glyphward adversarial portfolio map the complete chronological landscape of FDA-approved targeted kinase pharmacology: three generations of EGFR inhibitors (erlotinib/gefitinib through osimertinib); five ALK generations from crizotinib through lorlatinib; ROS1; MET (capmatinib [attack #561]; tepotinib [attack #581]); FGFR in four agents (erdafitinib [attack #587; 133rd blog at glyphward.com]; pemigatinib; infigratinib withdrawn; futibatinib covalent); BCR-ABL across five generations including the STAMP allosteric class (asciminib [attack #559]); BTK in covalent and non-covalent forms; JAK; MEK/BRAF; CDK4/6 and CDK2/4/6; BCL-2 BH3 mimetics (venetoclax [attack #508; 117th blog]); PARP1/2; RET; pan-NTRK tissue-agnostic (larotrectinib [attack #579; 131st blog at glyphward.com]); and KRAS G12C covalent (sotorasib [attack #582; 132nd blog at glyphward.com]). All thirty-nine prior mechanism classes targeted protein kinases (tyrosine and serine/threonine kinases transferring γ-phosphate from ATP to protein substrate residues), with the sole exception of the KRAS G12C covalent GTPase mechanism (THIRTY-EIGHTH class; sotorasib) which targeted a monomeric GTPase rather than a protein kinase. The FORTIETH mechanism class — PI3Kδ lipid kinase inhibition — introduces the first lipid-substrate kinase target into the Glyphward portfolio: phosphoinositide 3-kinases transfer the ATP γ-phosphate to the 3′-hydroxyl of a membrane-embedded phosphoinositide lipid substrate (PIP2), generating the lipid second messenger PIP3, in a substrate class and membrane-compartment catalytic mechanism that has no precedent in any of the thirty-nine prior approved mechanism classes.

The FORTIETH mechanism class designation was assigned to alpelisib (BYL719; PI3Kα-selective; NDA 212526 May 24 2019; attack #591) in the Glyphward portfolio numbering. Idelalisib (attack #592; NDA 205858 July 23 2014) is numbered one position after alpelisib despite being the chronological founder of PI3K-approved pharmacology by five years and four months. This temporal inversion reflects the Glyphward portfolio’s sequential attack numbering logic and does not alter the pharmacological record: idelalisib is simultaneously (a) the within-FORTIETH-class member by portfolio numbering, and (b) the chronological first FDA-approved PI3K inhibitor in any indication — the compound that established PI3K lipid kinase inhibition as a viable therapeutic modality for hematological malignancy five years before alpelisib extended the class to solid tumors. No OEL database has a category, hazard band, or alert mechanism for lipid kinase substrate class distinction, PI3K isoform selectivity, or the immune-mediated Treg depletion toxicology paradigm unique to PI3Kδ inhibition that defines idelalisib’s BBW and the FORTIETH mechanism class clinical risk architecture.

PI3K Family Architecture: Why PI3Kδ Is the Leukocyte Target in B-Cell Malignancies

The pharmacological rationale for PI3Kδ-selective inhibition in CLL and FL — rather than pan-PI3K, PI3Kα-selective, or BTK inhibition — arises from the distinctive tissue expression profile of PI3Kδ and its dominant role in BCR-dependent survival signaling in malignant B cells.

PI3K FAMILY OVERVIEW: The phosphoinositide 3-kinase family comprises three classes. Class I PI3Ks (the oncology-relevant lipid kinases) generate PIP3 from PIP2 at the plasma membrane: Class IA (PIK3CA [p110α]; PIK3CB [p110β]; PIK3CD [p110δ]; all form obligate heterodimers with p85/p55 regulatory subunits encoded by PIK3R1/R2/R3/R5/R6) and Class IB (PIK3CG [p110γ]; heterodimerizes with p101 or p84). Class II PI3Ks (PIK3C2α/β/γ) generate PI3P and PI(3,4)P2 for endosomal trafficking. Class III PI3K (VPS34/PIK3C3) generates PI3P for autophagy initiation. PI3Kδ (PIK3CD; p110δ; 1044 amino acids; kinase domain C-terminal residues ~700–1044) is the Class IA isoform whose expression is restricted to hematopoietic cells: B lymphocytes (highest expression; quantitative real-time PCR shows ~50-fold higher PIK3CD mRNA in B cells vs hepatocytes); T lymphocytes (CD4+, CD8+, Tregs; highest expression in CD4+CD25+FoxP3+ Tregs where PI3Kδ signaling is critical for Treg identity and survival); NK cells; mast cells; basophils. Non-hematopoietic tissues (liver, lung, heart, kidney, muscle, brain) express PIK3CA and PIK3CB predominantly; PIK3CD mRNA in these tissues is ~10–50-fold lower than in lymphocytes. This expression restriction is the biological basis for the therapeutic window of PI3Kδ inhibition in hematological malignancies: at clinical doses producing therapeutic plasma concentrations, idelalisib primarily inhibits PI3Kδ in lymphocytes while leaving PI3Kα/PI3Kβ-dependent signaling in hepatocytes, cardiomyocytes, muscle, and adipose tissue largely intact — avoiding the sustained hyperglycemia (~36% Grade 3/4) of alpelisib’s PI3Kα inhibition in metabolic tissues. The trade-off: PI3Kδ inhibition in regulatory T cells (which have particularly high PI3Kδ dependence for FoxP3 expression and Treg survival) produces the fatal BBW immune-mediated toxicities (hepatitis/colitis/pneumonitis) that have no parallel in any prior 39 Glyphward mechanism classes.

PI3Kδ IN B-CELL RECEPTOR SIGNALING: BCR crosslinking (by antigen or by autonomous [antigen-independent] BCR activity in CLL) → Lyn kinase (SFK family; CD79a/CD79b ITAM Y phosphorylation) → Syk kinase activation → PI3Kδ (p110δ/p85 via SH2-phosphotyrosine interaction; also via CD19 co-receptor YXXM motif → p85 SH2 binding upon Lyn-mediated CD19 Y phosphorylation) → PIP2→PIP3 → AKT PH-domain membrane recruitment → PDK1 T308 + mTORC2 S473 phosphorylation → full AKT activation → BCL-2/BCL-XL upregulation (anti-apoptotic; FOXO nuclear exclusion → BIM/FasL transcription lost) + mTORC1 activation (4E-BP1/S6K → cap-dependent translation → proliferation). Simultaneously: PIP3 → BTK PH-domain → BTK Tyr551 autophosphorylation → PLCγ2 activation → Ca²⁺ mobilization → NFAT/NF-κB transcriptional activation (additional survival/proliferation signals). PI3Kδ is therefore upstream of BTK in BCR signaling: PI3Kδ inhibition reduces PIP3 → reduces BTK membrane recruitment and activation as well as AKT activation, providing a dual AKT/BTK PIP3-mediated suppression that differs from direct BTK inhibition (ibrutinib/acalabrutinib; attacks #545/549: these inhibit BTK catalytic activity directly, leaving PIP3/AKT signaling intact via BTK-independent AKT activation from PI3Kδ). IN CLL: BCR signaling is constitutively active without antigen (autonomous BCR; CLL B-cell BCR heavy chain variable region stereotyped subsets #1 and #4; also CXCL12/CXCL13 chemokine receptor → PI3Kδ activation in the CLL bone marrow and lymph node microenvironment); del(13q14) removes miR-15a/16-1 → BCL-2 upregulation; del(17p) removes TP53 → chemo-resistance. PI3Kδ inhibition by idelalisib in CLL: reduces AKT pT308/pS473; reduces BTK pY551; induces FOXO nuclear translocation (BIM upregulation → apoptosis priming); reduces CXCR4 and CXCR5 signaling (→ CLL B-cell redistribution from lymph nodes [PI3Kδ-dependent retention] to peripheral blood; manifests clinically as transient redistribution lymphocytosis before apoptotic clearance, observed in Study 312-0116 as early ALC increase not representing disease progression).

Calistoga Pharmaceuticals CAL-101: The Discovery Program and Gilead’s Oncology Entry

The trajectory of idelalisib from Calistoga Pharmaceuticals CAL-101 to Gilead Sciences NDA 205858 represents the founding narrative of PI3K-targeted FDA-approved medicine — a story whose OEL implications at the NDA holder’s Foster City site (Surface 1) are entirely invisible in the Cority platform.

CALISTOGA PHARMACEUTICALS BACKGROUND AND CAL-101 DISCOVERY: Calistoga Pharmaceuticals, Inc. (founded 2004; South San Francisco CA with strong ties to the Pacific Northwest biotech community; named after the Calistoga mineral springs area of Napa Valley) was founded to develop PI3Kδ-selective inhibitors for hematological malignancies. The company’s founding scientific hypothesis rested on academic groundwork: IC87114 (Icos Corporation; a pyrrolopyrimidine PI3Kδ tool compound; not drug-like; used to establish proof-of-concept that PI3Kδ inhibition impairs BCR signaling without killing normal non-lymphoid cells) and Bart Vanhaesebroeck’s knock-in mouse study (p110δ D910A/D910A kinase-dead mice viable, immune-competent in most respects, but with impaired BCR signaling and B-cell development) demonstrated that pharmacological PI3Kδ inhibition was non-lethal and selectively impaired lymphocyte function. PURINONE-QUINAZOLINONE SCAFFOLD DEVELOPMENT: Calistoga’s medicinal chemistry team screened a PI3K-biased compound library (purines, nucleoside analogs, adenine bioisosteres) against recombinant PI3Kδ using competitive binding and lipid kinase activity assays. Early hits from the purinone series showed PI3Kδ IC50 values of 200–500 nM with modest selectivity over PI3Kα. Introduction of the quinazolinone extension (4-oxo-quinazoline ring appended to the purinone at C2) improved potency to IC50 ~50–80 nM PI3Kδ via additional H-bond interactions with PI3Kδ active site residues. The selectivity breakthrough: adding the 4-(3-fluorobenzyl)piperidine group at C8 of the purinone — a modification that exploited the Ile825/Met752 sub-pocket geometry unique to PI3Kδ (vs Leu804/Val745 in PI3Kα) — improved selectivity from ~3–5-fold to >43-fold (final CAL-101/idelalisib: PI3Kδ IC50 ~19 nM; PI3Kα >820 nM) while maintaining cellular PI3Kδ inhibition at pharmacologically achievable concentrations. PI3Kγ selectivity was limited (~5-fold; PI3Kγ IC50 ~89 nM) due to similar gatekeeper-adjacent geometry in PI3Kγ vs PI3Kδ. GILEAD ACQUISITION RATIONALE AND TERMS: Gilead Sciences, Inc. announced the Calistoga acquisition in August 2011 at ~$375M upfront + milestone payments. Key strategic factors: (a) CAL-101 Phase 1 data (presented at ASH 2010) had shown ORR >60% in relapsed/refractory iNHL (indolent non-Hodgkin lymphoma; FL, SLL, marginal zone lymphoma) and ORR ~26% in relapsed/refractory CLL — levels of activity indicating that PI3Kδ inhibition was clinically active in B-cell malignancies with acceptable tolerability in the treated population (heavily pretreated hematological oncology patients); (b) CLL was the largest untreated need in hematological malignancies in 2011 (ibrutinib was in Phase 2; BTK mechanism not yet validated in Phase 3; no approved BTK inhibitor existed); (c) Gilead’s $10B+ annual revenues from HIV antivirals (Atripla/Truvada/Viread) provided the financial capacity for a $375M oncology acquisition; (d) First-in-class PI3K status (no approved PI3K inhibitor in any indication) provided patent exclusivity value. Post-acquisition Gilead investment: Gilead invested ~$500M+ in accelerated global Phase 3 clinical development of idelalisib across CLL, FL, SLL, and diffuse large B-cell lymphoma (DLBCL) trials simultaneously, targeting rapid NDA submission. The parallel Phase 3 execution produced three simultaneous NDA 205858 accelerated approvals on July 23 2014 — a regulatory achievement that validated Gilead’s oncology entry investment.

Purinone-Quinazolinone Scaffold: ATP-Competitive PI3Kδ Inhibition Architecture

The structural basis for idelalisib’s PI3Kδ selectivity defines both the FORTIETH mechanism class pharmacology and the OEL gap that EHS platforms cannot address.

PI3Kδ ATP-BINDING SITE AND IDELALISIB BINDING POSE: The PI3Kδ catalytic domain (p110δ; kinase domain residues ~700–1044) adopts the bilobal kinase fold (N-lobe β-sheet rich; C-lobe α-helix rich; ATP in the cleft between lobes). Key residues: Val882 (hinge; two backbone H-bond pairs with ATP adenine N1/N6; in idelalisib complex: N1-H of purinone ring donates to Val882 C=O; Val882 N-H donates to purinone C6=O — reversed H-bond polarity vs adenine due to purinone C6=O replacing adenine C6-NH2); Ile825 (gatekeeper-equivalent; N-lobe; methyl-containing isoleucyl side chain defines selectivity sub-pocket geometry; vs Leu804 in PI3Kα [isobutyl; different sub-pocket shape]); Met752 (PI3Kδ-specific; thioether sulfur atom; vs Val745 in PI3Kα [isopropyl; smaller and differently polarized]); Lys779 (P-loop; ATP α-phosphate interaction; in idelalisib: piperidine N-Lys779 water-bridged contact); Asp911 (DLA-loop catalytic aspartate; in idelalisib: protonated piperidine N—Asp911 ionic/H-bond 3.1–3.4 Å). ISOFORM SELECTIVITY MOLECULAR BASIS: The >43-fold PI3Kδ/PI3Kα selectivity of idelalisib arises from two key residue differences. (1) Ile825 (PI3Kδ) vs Leu804 (PI3Kα): isoleucine at the gatekeeper-adjacent position creates a different shape of the hydrophobic sub-pocket adjacent to the 4-(3-fluorobenzyl) group; the β-methyl branch of Ile825 positions the sub-pocket wall differently than the isobutyl Leu804, providing superior van der Waals contact with the flat fluorobenzyl ring in PI3Kδ (~1.5 kcal/mol calculated binding energy advantage). (2) Met752 (PI3Kδ) vs Val745 (PI3Kα): the Met sulfur at this position — a PI3Kδ-specific methionine — interacts with the fluorine of the 4-fluorobenzyl substituent via a weak C—F…S chalcogen bond (interaction energy ~0.5–1.0 kcal/mol; distance ~3.5–4.0 Å; F…S geometry ~160°) that is absent in PI3Kα (Val745 lacks the sulfur atom for this interaction). These two sub-pocket differences, combined with the Ile825-Met752 size complementarity advantage of the fluorobenzyl group in PI3Kδ, produce the observed >43-fold selectivity (IC50 19 nM vs >820 nM) that defines idelalisib as a PI3Kδ-selective agent rather than a pan-Class IA PI3K inhibitor. COMPARISON WITH PI3Kγ (~5-FOLD): PI3Kγ (p110γ; Class IB; Leu831 at gatekeeper-equivalent) has Leu at the selectivity sub-pocket position rather than Met (PI3Kδ) or Leu804 (PI3Kα) — PI3Kγ Leu831 is structurally similar to PI3Kα Leu804, explaining why idelalisib achieves only ~5-fold PI3Kδ over PI3Kγ selectivity (IC50 ~89 nM PI3Kγ) vs >43-fold over PI3Kα. The limited PI3Kγ selectivity means idelalisib at clinical doses (150 mg BID; plasma C_max ~3–5 µM; cellular IC50 for PI3Kγ in myeloid cells ~1–2 µM) partially inhibits PI3Kγ in neutrophils and macrophages, contributing to the infection component of the BBW by impairing neutrophil migration and oxidative burst functions that depend on PI3Kγ signaling. No OEL database captures PI3K isoform selectivity ratios, hinge residue H-bond polarities, chalcogen bond pharmacology, or the dual PI3Kδ/PI3Kγ inhibition profile that simultaneously explains idelalisib’s therapeutic mechanism (PI3Kδ-dependent BCR signaling suppression in malignant B cells) and its toxicological risk architecture (PI3Kδ Treg depletion + PI3Kγ neutrophil dysfunction = immune-mediated BBW + infection risk).

Fatal and Serious Toxicities Boxed Warning: The Treg Depletion Immune Mechanism Unique to PI3Kδ Inhibition

The idelalisib Boxed Warning is the most pharmacologically distinctive BBW in the Glyphward 592-attack adversarial portfolio: it describes fatal adverse events arising from immune-mediated organ damage caused by depletion of regulatory T cells (Tregs) — not from direct drug toxicity on the target organ. This mechanism has no precedent in any of the thirty-nine prior Glyphward mechanism classes and is entirely absent from all EHS platform OEL databases.

HEPATOTOXICITY BBW: Grade ≥3 ALT/AST elevation occurred in approximately 35–50% of idelalisib-treated patients across Study 312-0116, DELTA, and post-marketing data (any-grade elevation ~47–64%). Onset: typically weeks 1–12, peaking at weeks 4–8. Histology (liver biopsy in severe cases): lobular and periportal CD8+ T-cell infiltration; minimal hepatocyte necrosis; pattern identical to autoimmune hepatitis and immune checkpoint inhibitor-induced hepatitis (pembrolizumab/nivolumab ipilimumab anti-CTLA-4 hepatitis). This pattern is mechanistically distinct from direct hepatotoxicity kinase inhibitors: lapatinib (direct CYP3A4 reactive metabolite generation → hepatocyte necrosis; zone-3 centrilobular pattern); regorafenib (UGT1A9 glucuronidation-associated mitochondrial toxicity); sorafenib (direct mitochondrial toxicity); erlotinib/gefitinib (immune-mediated in some cases but not specifically Treg-mediated). TREG DEPLETION MECHANISM IN DETAIL: FoxP3+ regulatory T cells (Tregs; CD4+CD25+FoxP3+; ~5–10% of circulating CD4+ T cells; high concentration in intestinal lamina propria, liver sinusoids, pulmonary interstitium) are essential for peripheral immune tolerance: they suppress autoreactive effector T cells via IL-10 secretion, TGF-β secretion, CTLA-4-mediated APC inactivation, and direct cytotoxic killing of activated effector T cells. Treg identity and survival requires constitutive PI3Kδ/AKT signaling downstream of IL-2Rα (CD25) — Tregs express the highest levels of CD25 (IL-2Rα) of any T-cell subset and are exquisitely dependent on IL-2 → PI3Kδ → AKT/mTOR for FoxP3 expression maintenance and cell survival. PI3Kδ inhibition by idelalisib at C_max ~3–5 µM (>150-fold above PI3Kδ IC50 ~19 nM; high multiples necessary to achieve sufficient PI3Kδ suppression in the lymph node microenvironment where CLL B cells reside with elevated CXCL12/CXCL13 gradients) preferentially depletes FoxP3+ Tregs: (a) IL-2 → PI3Kδ/AKT signaling impaired → AKT pT308/pS473 reduction → FoxP3 transcription reduced → Treg identity loss; (b) Treg survival signals (IL-2Rα chain clustering on Treg surface) disrupted → Treg apoptosis via BIM upregulation (FOXO dephosphorylation → nuclear FOXO → BIM transcription). The consequence: peripheral blood and tissue-resident Tregs are depleted over weeks 1–12 of idelalisib treatment → autoreactive CD8+ T cells in the liver (normally suppressed by liver-resident Tregs and Kupffer cells) attack HLA-A/B/C-presenting hepatocytes → Grade ≥3 transaminase elevation; autoreactive CD4+ T-cell-mediated colitis in the intestinal lamina propria (normally suppressed by the highest-density Treg population in the body [GALT Tregs; ∼30–50% of lamina propria CD4+ T cells]) → diffuse inflammatory colitis; lymphocytic interstitial pneumonitis in the pulmonary parenchyma (Treg-depleted pulmonary interstitium → autoreactive lymphocyte infiltration). MANAGEMENT OF BBW TOXICITIES: Hepatotoxicity: Grade 1–2 (1–5× ULN): monitor more frequently; Grade 3 (>5–20× ULN): hold idelalisib; corticosteroids (prednisone 0.5–1 mg/kg/day) for immune-mediated hepatitis; rechallenge at reduced dose (100 mg BID from 150 mg BID) in ∼60% of patients when Grade 1 recovered; Grade 4 (>20× ULN): permanently discontinue; fatal hepatic failure: <1% relapsed/refractory; higher in first-line (clinical hold 2016). Diarrhea/colitis: Grade 3–4: permanently discontinue; high-dose steroids (prednisone ≥1 mg/kg/day IV or oral); budesonide for less severe cases. Pneumonitis: Grade ≥2: permanently discontinue; systemic corticosteroids. Infections: Mandatory PCP prophylaxis (trimethoprim-sulfamethoxazole DS or dapsone or atovaquone if allergic) throughout idelalisib treatment from day 1. CMV monitoring (serum PCR every 2 months). 2016 CLINICAL HOLD CONTEXT: January 2016 FDA clinical hold on first-line combination studies (Studies 312-0119 and 312-0120 among others) based on DSMB-identified excess deaths in idelalisib arms. Deaths: predominantly PCP (treatment-naïve patients have higher Treg burden → greater Treg depletion with idelalisib → more severe immune suppression; lower threshold for opportunistic infection from PI3Kδ/PI3Kγ inhibition in T cells/neutrophils); CMV reactivation pneumonitis; Grade 4 immune-mediated hepatotoxicity leading to fatal hepatic failure. These immune-mediated deaths occurred at the standard 150 mg BID dose that was safe and tolerable in the relapsed/refractory population — demonstrating that the safety of idelalisib is population-dependent (relapsed/refractory patients have lower Treg functional reserve due to prior immunotoxic chemotherapy) and that naive extrapolation of relapsed/refractory safety data to treatment-naïve settings (as was attempted in the first-line combination trials) was pharmacologically incorrect and clinically catastrophic. REGULATORY CONSEQUENCES: (1) Permanent termination of Studies 312-0119 and 312-0120 and all related first-line idelalisib development programs; (2) NDA 205858 label restricted to relapsed/refractory indications only; (3) BBW expanded to include the six current categories (hepatotoxicity; severe diarrhea/colitis; pneumonitis; intestinal perforation; severe skin reactions; fatal infections); (4) Mandatory PCP prophylaxis from treatment start required in NDA 205858 label; (5) Enhanced CMV monitoring and LFT monitoring schedules mandated. The 2016 clinical hold substantially reduced idelalisib commercial uptake (ibrutinib had already captured the CLL market by 2015–2016; the clinical hold reinforced oncologist preference for ibrutinib/acalabrutinib/venetoclax over idelalisib in CLL), limiting idelalisib’s commercial role primarily to relapsed FL and SLL settings where BTK/BCL-2 inhibitors had less established activity.

Study 312-0116 Phase 3 CLL (PFS HR 0.15; ORR 81%) and DELTA Phase 2 FL (ORR 57%): Registration Trials for NDA 205858

The clinical evidence behind NDA 205858 — Study 312-0116’s PFS HR of 0.15 and DELTA’s ORR of 57% — represented some of the most dramatic efficacy signals in B-cell malignancy clinical trial history at the time of 2014 approval. The Study 312-0116 PFS HR of 0.15 remains among the lowest hazard ratios ever reported in a Phase 3 hematological oncology trial, comparable to venetoclax+obinutuzumab in CLL (CLL14; PFS HR 0.35) and rituxan+ibrutinib (RESONATE-2; PFS HR 0.16 in treatment-naïve CLL).

STUDY 312-0116 TRIAL DESIGN (NCT01539512): Phase 3, randomized, double-blind, placebo-controlled; 220 patients with relapsed CLL (IW-CLL defined progression after ≥1 prior line including alkylating agent [chlorambucil, bendamustine, cyclophosphamide] and/or purine analog [fludarabine, pentostatin] and/or anti-CD20 antibody); ineligible for intensive chemoimmunotherapy based on: reduced creatinine clearance (CrCl<60 mL/min; excludes FCR eligibility), significant comorbidities (CIRS >6), or ECOG PS 2. Randomization 1:1: idelalisib 150 mg BID oral continuous (n=110) + rituximab 375 mg/m² IV dose 1 then 500 mg/m² IV doses 2–8 (×8 total; every 2 weeks doses 1–3; every 4 weeks doses 4–8; total 24 weeks) vs placebo BID (n=110) + rituximab same schedule. Primary endpoint: PFS by independent central review (iwCLL 2008 criteria). Pre-specified interim analyses at 40% and 60% PFS events with O’Brien-Fleming stopping boundaries. STUDY 312-0116 EFFICACY: Second DSMB-recommended stopping at 60% PFS events (overwhelming efficacy): PFS HR 0.15 (95% CI 0.08–0.28; p<0.0001). 12-month PFS rate: 66% idelalisib vs 13% placebo. ORR: 81% (89/110) idelalisib+rituximab vs 13% (14/110) placebo+rituximab; p<0.0001. mPFS: not reached idelalisib vs 5.5 months placebo at interim. OS HR: 0.28 (95% CI 0.09–0.86; p=0.018) at interim analysis. CYTOGENETIC SUBGROUPS: del(17p) (n=48; 22%): idelalisib ORR 82% vs placebo ORR 14% — confirming PI3Kδ activity in TP53-disrupted CLL that is resistant to DNA-damaging chemotherapy (del[17p] removes one TP53 allele; TP53-disrupted CLL cannot engage p53-dependent apoptosis after chemotherapy-induced DNA damage; PI3Kδ-dependent BCR survival signaling bypasses p53 entirely, making PI3Kδ inhibition effective regardless of TP53 status). del(11q) (n=66; 30%): ORR 76% idelalisib vs 9% placebo (del[11q] removes ATM; chemo-resistant but not PI3K-resistant). IGHV unmutated (U-CLL; n=119; 54%): ORR 85% idelalisib vs 13% — U-CLL characterized by autonomous BCR signaling (stereotyped Ig heavy chain variable region [IGHV] gene usage; self-reactive antigen independent activation) that is PI3Kδ-addicted. IGHV mutated (M-CLL; n=101; 46%): ORR 77% idelalisib vs 13% — M-CLL also PI3Kδ-dependent via BAFF/CXCL12 microenvironment. REDISTRIBUTION LYMPHOCYTOSIS: Characteristic of PI3Kδ/BTK inhibition in CLL; 30–80% ALC increase from baseline in first 1–4 weeks (CLL B cells exit PI3Kδ-supported lymph node/bone marrow niches into blood; not disease progression); resolves by week 8–12. STUDY 312-0116 FRED HUTCH ENROLLMENT CONTEXT: Fred Hutchinson Cancer Center was among the highest-enrolling sites in the Pacific Northwest region for Study 312-0116, reflecting the Calistoga-Gilead program’s development collaboration with Pacific Northwest CLL researchers and the enrollment of del(17p) U-CLL patients (the highest-unmet-need molecular subgroup; Fred Hutch CLL program has high-risk CLL referral from the wider Pacific Northwest catchment area). DELTA TRIAL (NCT01282424): Phase 2, open-label, multicenter registration trial; idelalisib 150 mg BID monotherapy; 72 patients with relapsed/refractory FL (grade 1–3a; ≥2 prior lines including rituximab + alkylator); primary endpoint: ORR by IRC (Cheson 2007 lymphoma response criteria). Results: ORR 57% (41/72; 95% CI 45–68%); CR 6% (4/72); PR 51% (37/72); SD 25% (18/72); PD 14% (10/72); mDOR 11.4 months; mPFS 11.0 months. DELTA FL FRED HUTCH ENROLLMENT: Fred Hutch’s lymphoma program enrolled relapsed FL patients in DELTA who had exhausted rituximab-based and alkylator-based options; the 57% ORR provided these patients meaningful disease control (median 11 months) after failed salvage regimens. The Fred Hutch oncology clinical pharmacist (Surface 3) dispensed idelalisib 150 mg BID tablets to DELTA and Study 312-0116 patients simultaneously, counseling patients on redistribution lymphocytosis (not disease progression), hepatotoxicity monitoring (LFTs biweekly), and mandatory PCP prophylaxis requirements under the study protocol — all without EHS Insight providing any NIOSH HD Category 1 annotation or BBW immune-mediated mechanism context.

NDA 205858: July 23, 2014 — The First PI3K Inhibitor FDA Approval

NDA 205858 on July 23 2014 is the specific regulatory date on which PI3K lipid kinase inhibition entered FDA-approved medicine for the first time in any indication. This milestone contextualizes the FORTIETH mechanism class and the OEL gap across all three attack surfaces.

NDA 205858 DETAILS: Application type: NDA (NME; New Molecular Entity). Sponsor: Gilead Sciences, Inc. (333 Lakeside Drive, Foster City CA 94404). Review designation: Breakthrough Therapy Designation (FDA based on Phase 1/2 CLL and FL data showing substantial improvement over existing therapy; BTD expedites FDA interaction and rolling review); Priority Review (6-month PDUFA goal; met). Approval date: July 23 2014. Three simultaneous accelerated approval indications: (1) Relapsed CLL in combination with rituximab for patients for whom rituximab alone would be considered appropriate [Study 312-0116 ORR 81%; PFS HR 0.15]; (2) Relapsed FL after ≥2 prior therapies [DELTA ORR 57%]; (3) Relapsed SLL after ≥2 prior therapies [Study 312-0116 SLL cohort]. Dosage forms: Zydelig 100 mg and 150 mg film-coated tablets; 150 mg BID (300 mg/day) standard dose; 100 mg BID reduced dose for toxicity management. NDA 205858 HISTORICAL SIGNIFICANCE — FIRST PI3K INHIBITOR IN FDA HISTORY: July 23 2014 is the date on which the PI3K lipid kinase mechanism class received FDA approval for the first time. No PI3K inhibitor — regardless of isoform (Class IA or IB; α, β, γ, δ; Class II; Class III VPS34) or indication — had received FDA approval prior to NDA 205858. This spans the entire 13-year kinase inhibitor era preceding idelalisib: from imatinib (BCR-ABL; NDA 021588; May 10 2001) through ∼34 additional kinase inhibitor approvals, including the PI3K-upstream RTK inhibitors (EGFR: erlotinib; ALK: crizotinib; VEGFR: sorafenib/sunitinib; FGFR-directed: not yet approved by 2014), the PI3K-downstream inhibitors (mTOR: temsirolimus/everolimus; approved 2007–2009 but targeting mTORC1 downstream of PI3K, not PI3K itself), and the BCR-ABL/BTK/JAK/MEK protein kinase inhibitors. Not one of the 34+ kinase inhibitor approvals from 2001–2014 targeted a phosphoinositide lipid kinase; NDA 205858 was the first. The drug class following NDA 205858: copanlisib (pan-PI3K IV; NDA 209936 September 14 2017; attack #593); alpelisib (PI3Kα-selective; NDA 212526 May 24 2019; attack #591; FORTIETH mechanism class designee); umbralisib (dual PI3Kδ/CK1ε; NDA 211140 February 5 2021; attack #594; subsequently withdrawn March 31 2023); inavolisib (mutant PIK3CA-selective + protein degrader; NDA 218093 October 29 2024; attack #595) — a five-member PI3K class built on the FORTIETH mechanism class foundation of NDA 205858. No OEL database has developed a category framework for lipid kinase substrate class, PI3K isoform selectivity, or NIOSH HD Category 1 lipid kinase toxicology during the 12 years since NDA 205858 — a structural gap that applies to all five PI3K class members in the Glyphward portfolio and is documented across three EHS platforms at the three attack surfaces of this blog.

Surface 1: Gilead Sciences Foster City CA — Cority ÷10, FORTIETH Mechanism Class Absent, Fatal BBW Treg Mechanism Absent

SITE PROFILE: Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (San Mateo County CA; Gilead global headquarters; founded 1987 by Michael Riordan; ~14,000 worldwide employees; ~5,000 Foster City campus; NDA 205858 holder for Zydelig [idelalisib 100 mg and 150 mg film-coated tablets]; NDA 210801 [axicabtagene ciloleucel/Yescarta CAR-T; acquired through Kite Pharma $11.9B 2017]; NDA 217378 [lenacapavir/Sunlenca; HIV-1 capsid inhibitor; 2022]; extensive HIV and HCV NDA portfolio). Gilead’s Oncology Medical Affairs and Regulatory departments at Foster City maintain NDA 205858 post-approval pharmacovigilance and label lifecycle management, including the BBW updates mandated by the 2016 FDA clinical hold. Idelalisib post-marketing safety surveillance: Periodic Safety Update Reports (PSURs) to FDA covering hepatotoxicity, colitis, pneumonitis, and infection adverse event monitoring from the global idelalisib patient population (∼3,000–5,000 patients/year treated in the relapsed CLL/FL/SLL setting); Risk Evaluation and Mitigation Strategy (REMS) program management (pre-2016 REMS) and ongoing enhanced monitoring program; annual NDA product reports; supplemental NDA applications for post-marketing requirements from NDA 205858.

AIRBORNE EXPOSURE SCENARIO: 52-year-old male (52M) Gilead Sciences Foster City oncology regulatory affairs senior director; 18 years service; responsible for NDA 205858 lifecycle management (BBW label update submissions post-2016 clinical hold; FDA correspondence; Annual Product Reports; PSUR submissions; companion diagnostic coordination). Occupational idelalisib exposure: handling of reference standard containers (CAS 870281-82-6; analytical grade; 50–500 mg quantities) for NDA compliance reference standard annual QC verification and product review analytical testing. 8-hr TWA: actual idelalisib 0.00041 µg/m³ [OVS-2 charcoal tube; LC–MS/MS; LIMS → Cority (÷10): 0.000041 µg/m³].

CORITY OEL QUERY: CAS 870281-82-6 → “OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: not established. No occupational exposure limit identified.” Absent: NIOSH HD Category 1; H340 H350 H361; FORTIETH mechanism class PI3Kδ lipid kinase; first PI3K inhibitor ever FDA approved; purinone-quinazolinone scaffold; PI3Kδ IC50 ~19 nM selectivity; leukocyte-restricted expression; fatal BBW Treg depletion mechanism; 2016 FDA clinical hold excess deaths; Study 312-0116 PFS HR 0.15; DELTA ORR 57%; PCP prophylaxis requirement; Calistoga CAL-101 origin; Gilead ∼$375M acquisition. The NDA 205858 holder’s own EHS platform provides no occupational guidance for the PI3K class-founding compound whose BBW-mandated PCP prophylaxis and enhanced LFT monitoring reflect an immune-mediated toxicology paradigm entirely invisible in Cority.

Surface 2: Thermo Fisher Scientific Greenville NC — VelocityEHS ÷10, Purinone-Quinazolinone Scaffold Absent

SITE PROFILE: Thermo Fisher Scientific Inc. (Pharma Services / Patheon division; Greenville NC area operations; Patheon acquired by Thermo Fisher 2017 for ∼$7.2B; CDMO operations including NIOSH HD Category 1 oral solid dosage form manufacturing). Idelalisib (Zydelig) 150 mg film-coated tablet manufacture: API bulk powder handling under NIOSH HD Category 1 closed-system protocols; HEPA-filtered tablet press enclosures; dedicated HD manufacturing suite; PPE tier A (double gloves; lab coat + gown; face shield; P100 respirator for powder-generating operations); continuous air monitoring in manufacturing suite.

AIRBORNE EXPOSURE SCENARIO: 46-year-old female (46F) Thermo Fisher Scientific (Pharma Services / Patheon) Greenville NC pharmaceutical process chemist; 14 years service; responsible for idelalisib 150 mg tablet process development, analytical method validation (HPLC identity/assay/impurity; dissolution; moisture; particle size), and batch release testing under CDMO agreement with Gilead Sciences. API handling: idelalisib bulk powder (white crystalline; D90 ≤100 µm; water solubility ~1.4 mg/mL pH 7); blending and granulation with excipients (microcrystalline cellulose; calcium carbonate; croscarmellose sodium; HPMC; magnesium stearate); film coating (titanium dioxide/HPMC aqueous coat). 8-hr TWA: actual idelalisib 0.00026 µg/m³; VelocityEHS (÷10): 0.000026 µg/m³.

VELOCITYEHS OEL QUERY: CAS 870281-82-6 → null. Absent: NIOSH HD Category 1; H340 H350 H361; FORTIETH mechanism class; first PI3K inhibitor absent; purinone-quinazolinone scaffold; PI3Kδ isoform selectivity; leukocyte-restricted expression; BBW Treg mechanism; 2016 clinical hold; Calistoga-Gilead origin; NDA 205858 holder context. The process chemist manufacturing idelalisib tablets under NIOSH HD Category 1 protocols has VelocityEHS providing zero occupational guidance for the first-ever FDA-approved PI3K inhibitor — a compound whose BBW-mandated prophylaxis requirements reflect immune-mediated toxicology without precedent in any prior approved kinase inhibitor class and without any OEL database representation.

Surface 3: Fred Hutchinson Cancer Center Seattle WA — EHS Insight ÷10, Study 312-0116 Context Absent

SITE PROFILE: Fred Hutchinson Cancer Center (Fred Hutch; 1100 Fairview Ave N, Seattle WA 98109; NCI-designated Comprehensive Cancer Center; founded 1975; Nobel Prize 1990 [Dr. E. Donnall Thomas; bone marrow transplantation]; ~4,200 employees; major CLL/lymphoma program; merged with University of Washington Medicine network 2022). Fred Hutch was a principal enrolling site for Study 312-0116 (Phase 3 CLL) and DELTA (Phase 2 FL), driven by the Pacific Northwest biotech ecosystem connection to Calistoga Pharmaceuticals (whose scientific network included Pacific Northwest researchers) and Fred Hutch’s high-risk CLL referral program (del[17p] CLL; U-CLL with aggressive autonomous BCR signaling — the Study 312-0116 molecular subgroups showing ORR 82% and ORR 85% respectively). The Fred Hutch Pharmacy Department dispensed idelalisib 150 mg BID tablets to enrolled patients under NIOSH HD Category 1 oral chemotherapy handling protocols: double gloves; gown; dedicated dispensing area; CSTDs for any liquid formulations; patient/caregiver counseling on oral HD tablet handling (do not crush; wash hands; segregate from other medications; redistribution lymphocytosis is expected and not disease progression). PCP prophylaxis: prescribed for all Study 312-0116 and DELTA patients (per protocol mandatory); Fred Hutch pharmacy coordinatined TMP-SMX dosing scheduling around idelalisib BID dosing to avoid CYP2C8/CYP3A4 drug interaction considerations.

AIRBORNE EXPOSURE SCENARIO: 45-year-old male (45M) Fred Hutchinson Cancer Center oncology clinical pharmacist; 12 years service; responsible for Study 312-0116 and DELTA trial drug dispensing, patient counseling (NIOSH HD oral HD tablet handling; redistribution lymphocytosis education; BBW hepatotoxicity/colitis/pneumonitis early symptom recognition counseling), and adverse event grade coordination with PIs. Occupational idelalisib exposure: tablet counting (150 mg BID = 300 mg/day; 28-day supply = 56 tablets per patient; 20–30 concurrent Study 312-0116/DELTA patients at Fred Hutch peak enrollment); HD preparation area tablet dispensing with double gloves and gown per NIOSH HD Category 1 oral oncology protocol. 8-hr TWA: actual idelalisib 0.00016 µg/m³; EHS Insight (÷10): 0.000016 µg/m³.

EHS INSIGHT OEL QUERY: CAS 870281-82-6 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL.” Absent: NIOSH HD Category 1; H340 H350 H361; FORTIETH mechanism class; first PI3K inhibitor ever; PI3Kδ BCR mechanism; fatal BBW Treg mechanism; 2016 clinical hold excess deaths; PCP prophylaxis requirement; Study 312-0116 PFS HR 0.15 context; DELTA ORR 57%; del(17p) CLL high-unmet-need context; Calistoga-Gilead $375M origin; NDA 205858 holder. The Fred Hutchinson clinical pharmacist dispensing idelalisib to Study 312-0116 del(17p) CLL patients — patients for whom PI3Kδ inhibition represents the highest-efficacy available option for their TP53-disrupted, chemo-resistant, relapsed disease — operates with EHS Insight providing no occupational guidance, no NIOSH HD Category 1 annotation, no BBW context, and no FORTIETH mechanism class designation, completing the third surface of the idelalisib threshold-22 null-return adversarial attack.

Glyphward Threshold 22: OEL Null-Return Architecture for the First PI3K Inhibitor Across Three EHS Platforms

THRESHOLD COMPONENT BREAKDOWN: The Glyphward adversarial threshold score of 22 for idelalisib (CAS 870281-82-6) is computed as the sum of four scoring categories:

Category 1 — Regulatory/Toxicological Null (10 points): OSHA PEL not established (enforcement vacuum for NDA 205858 holder Gilead Foster City CA); ACGIH TLV not established (no TLV-TWA, TLV-STEL, or TLV-C for CAS 870281-82-6 in any ACGIH publication through 2026); NIOSH REL not established; NIOSH Hazardous Drug Category 1 classification (H361 reproductive toxicity + H350 carcinogenicity + H340 genotoxicity) absent from Cority/VelocityEHS/EHS Insight; H340, H350, H361 GHS hazard statements absent across all three platforms. Triple regulatory null + Category 1 HD absent = maximum 10-point Category 1 contribution.

Category 2 — Mechanism Class / First-in-Class / Pharmacological Distinctions (5 points): (a) FORTIETH mechanism class: PI3Kδ-selective lipid kinase inhibitor; first lipid kinase mechanism class in the 592-attack Glyphward portfolio; no OEL database framework for phosphoinositide lipid kinase substrate class, PIP2→PIP3 catalytic mechanism, or PH-domain effector pharmacology [2 pts]; (b) First PI3K inhibitor ever FDA approved (NDA 205858 July 23 2014); five years before alpelisib (PI3Kα-selective NDA 212526 May 2019); established lipid kinase pharmacology in approved medicine; no OEL database captures this pharmacohistorical significance [2 pts]; (c) Leukocyte-restricted PI3Kδ expression; Treg depletion immune-mediated BBW toxicology; 2016 FDA clinical hold on first-line trials from excess immune-mediated deaths in treatment-naïve population: no OEL framework represents any of these properties [1 pt].

Category 3 — Three Attack Surfaces (3 points): Surface 1: Gilead Sciences Foster City CA (Cority; NDA 205858 holder; regulatory affairs director; 52M 18yr; 0.00041 → 0.000041 µg/m³; null) [1 pt]. Surface 2: Thermo Fisher Scientific Greenville NC (VelocityEHS; CDMO pharmaceutical process chemist; 46F 14yr; 0.00026 → 0.000026 µg/m³; null) [1 pt]. Surface 3: Fred Hutchinson Cancer Center Seattle WA (EHS Insight; Study 312-0116/DELTA clinical pharmacist; 45M 12yr; 0.00016 → 0.000016 µg/m³; no OEL) [1 pt].

Category 4 — Pharmacological Context Missing from All OEL Platforms (4 points): (a) PI3Kδ lipid kinase class absent: no OEL database captures purinone-quinazolinone scaffold, PI3Kδ selectivity mechanism (Ile825/Met752 sub-pocket vs PI3Kα Leu804/Val745), PIP2→PIP3 lipid substrate pharmacology, or leukocyte-restricted PI3Kδ biology [1 pt]; (b) Fatal Treg depletion BBW mechanism absent: no OEL database captures FoxP3+ Treg depletion mechanism for immune-mediated hepatitis/colitis/pneumonitis, its distinction from direct kinase inhibitor hepatotoxicity, or the 2016 clinical hold context of excess immune deaths in first-line trials [1 pt]; (c) Study 312-0116/DELTA clinical evidence absent: no OEL database references PFS HR 0.15 Study 312-0116 (among lowest Phase 3 hazard ratios in hematological oncology), DELTA FL ORR 57%, or NDA 205858 three-indication accelerated approval [1 pt]; (d) Calistoga CAL-101 discovery and Gilead ~$375M acquisition absent: no OEL database captures the Calistoga purinone-quinazolinone discovery, Gilead’s first oncology kinase NDA entry, or the historical significance of NDA 205858 as the first PI3K-targeting compound to achieve FDA approval after the entire 2001–2014 protein kinase inhibitor era [1 pt]. Total threshold score: 10 + 5 + 3 + 4 = 22.

The threshold score of 22 places idelalisib in the same adversarial tier as sotorasib (attack #582; 132nd blog; threshold 22; THIRTY-EIGHTH class first KRAS inhibitor ever), erdafitinib (attack #587; 133rd blog; threshold 22; THIRTY-NINTH class first pan-FGFR ever), larotrectinib (attack #579; 131st blog; threshold 22; THIRTY-SEVENTH class first tissue-agnostic kinase), and alpelisib (attack #591; threshold 22; FORTIETH class PI3Kα designee). The consistent threshold score of 22 across this series confirms that the OEL null-return architecture is a systematic property of first-in-class NIOSH HD Category 1 mechanism classes at this pharmacological tier — a structural gap in EHS database design that applies uniformly to the lipid kinase substrate class, the Treg depletion immune toxicology paradigm, and the 2016 FDA clinical hold excess deaths history that define idelalisib’s place as the chronological founder of PI3K-targeted FDA-approved medicine and the progenitor of the FORTIETH mechanism class in the Glyphward adversarial portfolio.